Diabetes Treatment Insurance Claim Denied? How to Appeal

A denial for insulin pumps, continuous glucose monitors (CGMs), or GLP-1 medications can feel like your insurer is standing between you and your life. Diabetes management — whether Type 1 (ICD-10: E10) or Type 2 (ICD-10: E11) — is not elective care. It is a daily, medically necessary commitment backed by decades of clinical evidence and endorsed by every major diabetes medical organization. If your claim has been denied, you have real options to fight back.

Why Insurers Deny Diabetes Treatment Claims

Insurance companies frequently deny coverage for diabetes devices and medications for a handful of predictable reasons:

• Step therapy requirements for CGMs: Insurers often require documentation that a patient has first used traditional fingerstick blood glucose monitoring and that HbA1c control remains inadequate before approving a CGM such as the Dexcom G7 or Abbott FreeStyle Libre. Even when a physician prescribes a CGM as first-line for a patient with Type 1 diabetes, the insurer may demand proof of prior use of less expensive monitoring methods.
• BMI or HbA1c thresholds for insulin pumps: Continuous subcutaneous insulin infusion (CSII) pumps are often denied when the insurer applies rigid criteria — such as requiring an HbA1c above a certain level despite the patient already achieving reasonable control — perversely penalizing well-managed patients.
• GLP-1 and GIP/GLP-1 drug denials: Medications such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza) are routinely denied for diabetes management when insurers require Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization and evidence of step therapy failure. These drugs are supported by ADA Standards of Care 2025 as preferred agents for patients with Type 2 diabetes who have cardiovascular disease or are at high cardiovascular risk.
• Formulary exclusions: The prescribed brand may not appear on the plan formulary, and the insurer refuses to approve a formulary exception even when the in-formulary alternatives have documented contraindications or have previously failed.
• Durable medical equipment (DME) coverage disputes: Insulin pumps are classified as DME under most plans; denials sometimes arise from technicalities in the DME benefit, such as requirements that the equipment be obtained from a specific DME supplier or that specific HCPCS codes are used.
• Lack of specialist documentation: Some plans require a board-certified endocrinologist's order or documented failure of treatment by a primary care physician before approving intensive diabetes management technology.

How to Appeal a Diabetes Treatment Denial

Step 1: Identify the Exact Denial Reason

Your EOB)" class="auto-link">Explanation of Benefits (EOB) and denial letter must state the specific reason for denial. Common denial codes include "not medically necessary," "prior authorization required," "step therapy criteria not met," and "non-covered service." Each reason requires a different appeal argument, so precision here is essential.

Step 2: Request the Insurer's Clinical Coverage Criteria

You are entitled to the specific clinical coverage criteria the insurer applied. Ask for the plan's CGM coverage policy, insulin pump policy, or GLP-1 formulary exception criteria in writing. Compare these criteria against ADA Standards of Care 2025 guidelines — which explicitly recommend CGMs for all insulin-using patients and GLP-1 agonists for patients with Type 2 diabetes and cardiovascular risk — and document any gaps.

Step 3: Obtain an Endocrinologist Letter of Medical Necessity

A detailed Letter of Medical Necessity from a board-certified endocrinologist is the single most important document in a diabetes technology appeal. The letter should cite your most recent HbA1c values, history of hypoglycemic episodes (particularly severe or nocturnal events), frequency of glucose variability, and the specific clinical rationale for the requested device or medication. Reference ADA Standards of Care Section 7 (Diabetes Technology) and Section 9 (Pharmacologic Approaches) as applicable.

Step 4: Invoke Step Therapy Override Rights

Over 30 states have enacted step therapy override laws requiring insurers to approve a prescribed medication when step therapy alternatives have been contraindicated, previously failed, or are clinically inappropriate. If your state has such a law — including California, New York, Texas, Illinois, and many others — cite it explicitly in your appeal. For ERISA-governed employer plans, request a formulary exception under the plan's own Exception and Appeals procedures.

Step 5: Document the Clinical Impact of Denial

Gather evidence of the harm caused or likely to be caused by the denial — emergency department visits related to hypoglycemia, hospitalizations for diabetic ketoacidosis (DKA), or documented HbA1c deterioration since coverage lapsed. Under most medical necessity frameworks, a treatment that reduces hospitalizations and emergency care is cost-effective and clinically appropriate even when its upfront cost is higher.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review

If the internal appeal fails, file for external review under the ACA. An IROs) Explained" class="auto-link">Independent Review Organization (IRO) will evaluate the denial against broadly accepted medical standards — not the insurer's proprietary criteria — and the decision is binding on the insurer. For diabetes technology and GLP-1 denials supported by ADA guidelines, external reviews are overturned at meaningful rates.

What to Include in Your Diabetes Treatment Appeal

• Endocrinologist Letter of Medical Necessity citing ICD-10 E10 or E11, ADA Standards of Care 2025, and specific clinical rationale for the requested device or drug
• Recent HbA1c lab results, continuous glucose monitoring data (if available), and records of hypoglycemic events
• Documentation of prior treatments attempted, failed, or contraindicated, addressing any step therapy requirements
• The insurer's specific coverage criteria document alongside published ADA or AACE guidelines demonstrating alignment with accepted clinical standards
• State step therapy override law citation if applicable, or formulary exception request form if the issue is a non-formulary drug

Fight Back With ClaimBack

A diabetes treatment denial often comes down to documentation gaps, not a genuine clinical disagreement — and the right appeal letter can close that gap quickly. ClaimBack generates a professional, evidence-based appeal citing ADA guidelines, your specific diagnosis codes, and your insurer's own coverage criteria in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal